Teva Pharmaceutical Industries (TEVA) Q4 2024 Earnings Call Transcript
Hello, and welcome to the fourth quarter and full year 2024 Teva Pharmaceutical Industries earnings conference call. My name is Alex, and I will be coordinating the call today. [Operator instructions] And I hand it over to your host, Chris Stevo, SVP, investor relations. Please go ahead.
Teva Pharm tops quarterly estimates but 2025 earnings outlook falls short
Teva Pharmaceutical Industries reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit sales gains in a trio of its branded drugs to treat migraines, Huntington's disease and schizophrenia.
Teva Pharmaceutical Shares Fall 13% Following Lower-than-Expected Q4 Results
Teva Pharmaceutical Industries Ltd. (TEVA) has seen a decline of 13.92 percent in its stock value during Wednesday afternoon trading
Crude Oil Down 1.5%; Teva Pharmaceutical Shares Plummet
European shares were mostly higher today. The eurozone's STOXX 600 rose 0.50%, Germany's DAX 40 gained 0.97% and France's CAC 40 fell 0.32%. Spain's IBEX 35 Index rose 1.09%, while London's FTSE 100 rose 0.28%.
Teva Pharm Q4 tops estimates on strong sales of its own drugs
Teva Pharmaceutical Industries reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit sales gains in a trio of its branded drugs to treat migraines, Huntington's disease and schizophrenia.
Teva Pharmaceutical shares tumble as 2025 outlook disappoints
NEW YORK - Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported fourth-quarter earnings that beat analyst estimates, but its shares fell sharply as the company's 2025 outlook came in below expectations.
Teva Pharmaceutical Stock Falls On Q4 Earnings: What's Going On?
Teva reported fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion, according to Benzinga Pro. The company reported fourth-quarter adjusted earnings of 71 cents per share,
Teva slips as 2025 earnings outlook misses estimates
Teva Pharmaceutical (NYSE:TEVA) lost ~5% in the premarket even after recording better-than-expected financials for Q4 2024 on Wednesday, as the generic drugmaker set its 2025 earnings outlook below consensus.
Why Teva Pharmaceutical Stock Is Sinking Today
Shares of Teva Pharmaceutical Industries ( TEVA -13.66%) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p ...
Teva Pharma CEO: Guidance based on the new Teva that grows every year
Richard Francis, Teva Pharmaceuticals CEO, joins 'Money Movers' to discuss the company's quarterly earnings results, drug ...
FiercePharma2h
Teva, despite delivering in 2024, startles investors with subdued 2025 guidance
Despite finishing strong across both its innovative and generic businesses in 2024, Teva’s cautious approach to the new year ...
Teva price target lowered to $23 from $26 at BofA
BofA analyst Jason Gerberry lowered the firm’s price target on Teva (TEVA) to $23 from $26 and keeps a Buy rating on the shares. For FY25, the ...
globes.co.il6h
Teva falls sharply on disappointing 2025 guidance
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA has opened the reporting season for Israeli companies by ...
JD Supra1h
Alvotech and Teva Announce Acceptance of BLA for AVT05, a Golimumab Biosimilar
Alvotech and Teva announced FDA acceptance of the Biologics License Application (BLA) for AVT05, a proposed biosimilar ...
Hosted on MSN1h
Teva Stock Dives 14%. Why Its CEO Says It's A Victim.
Teva Pharmaceutical is a victim of its own success, Chief Executive Richard Francis said Wednesday as Teva stock plummeted on ...